Precision Microbiota Interventions for Senoreduction Trial
Key claim: A randomized, double-blind, crossover trial is evaluating two GRAS microbiota-targeted interventions on immune senescence biomarkers in people with HIV who drink alcohol.
Abstract
People with HIV who drink alcohol are at increased risk for accelerated aging biology, including increased immune senescence. This randomized, double-blind, crossover clinical trial evaluates two generally recognized as safe (GRAS) microbiota-targeted interventions on immune senescence biomarkers.
Why this matters
Microbiota-aimed ‘senoreduction’ is an emerging angle that borrows the senotherapeutics vocabulary without the senolytic drug risk profile, and this trial is one of the first to put it into a randomized clinical test in a population where immune aging is accelerated. Because the interventions are GRAS, the trend-to-evidence gap here is narrower than for peptide or biologic senolytics, but there is still no readout — the study is a probe, not a result.